Back

Thymosin mitigates immune checkpoint inhibitor-induced cardiotoxicity in cancer patients

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology and immunity Cancer Biology and Treatment ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr Hongjian Dong

Zhongda Hospital, Southeast University, Nanjing (China)

6 More presentations in this session

Presentation thumbnail
The risk of cardiovascular death in systemic immune-mediated diseases: a systematic review and meta-analysis.
Mr L. Cambini (Rozzano, IT)
Abstract Slides Video
Presentation thumbnail
To compare epicardial fat thickness with carotid intimal media thickness in predicting cardiovascular risk in patients with systemic lupus erythematosus
Doctor S. Singh (New Delhi, IN)
Abstract Slides Video
Presentation thumbnail
Heart failure as a frequent bystander in sarcoidosis - characterization of sarcoidosis patients with and without heart failure.
Miss A. Skwarek (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Cancer increases heart failure risk in people with diabetes
Doctor J. Wong (Melbourne, AU) Professor T. Marwick (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
The predictive value of follow-up troponin measurements in patients treated with immune checkpoint inhibitors
Doctor M. Laufer-Perl (Tel Aviv, IL)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology and immunity

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Cardiovascular risks of PD1 inhibitor therapy in cancer: impact of prior ischemic events on heart failure - a retrospective cohort study
thumbnail
Congress Presentation
Cardiovascular adverse events in primary lung cancer patients treated with immune checkpoint inhibitors: a nationwide database study
thumbnail
Congress Presentation
Cardiovascular disease and its association with outcomes in cancer patients treated with immune checkpoint inhibitors

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources